Why Eli Lilly Stock Is Sinking Today

Shares of Eli Lilly (NYSE: LLY) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) gained 1% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 1.9%.

The pharmaceutical giant released earnings that disappointed investors despite strong sales growth. The company lowered its full-year 2025 profit outlook following a recent cancer treatment acquisition deal.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Eli Lilly posts positive numbers

Eli Lilly's Q1 report showed strong earnings and sales growth. The company posted adjusted earnings per share (EPS) of $3.34 on $12.73 billion in sales. Wall Street had expected $3.02 on $12.67 billion.

The positive performance was driven by the company's blockbuster GLP-1 drugs Mounjaro and Zepbound. Mounjaro, used to help treat diabetes, saw sales more than double year over year to $3.84 billion. Zepbound was up more than 300%, reaching $2.31 billion in sales.

The earnings forecast was cut

Despite the performance, the company lowered its earnings expectations for 2025. While maintaining its revenue forecast of $58 billion to $61 billion, the company expects EPS of $20.78 and $22.28, down from $22.50 to $24 per share. The change comes mostly from a $1.57 billion charge recorded in Q1 from the company's acquisition of a cancer treatment.

The company also noted that although the numbers reflect all existing tariffs, they do not account for President Trump's planned levies on pharmaceuticals. The new tariffs could further impact the company's bottom line.

Eli Lilly's stock isn't cheap

The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk.

Still, as an American company with significant domestic manufacturing, Eli Lilly could end up impacted less by Trump's tariffs than its Danish counterpart. The incredible growth driven by these blockbuster GLP-1s is likely to continue for some time -- currently about 6% of U.S. adults regularly take a GLP-1, while a whopping 42% are would qualify as eligible. Given this, I think its valuation is justified.

Should you invest $1,000 in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $610,327!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $667,581!*

Now, it’s worth noting Stock Advisor’s total average return is 882% — a market-crushing outperformance compared to 161% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 28, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.